Efficacy of tocilizumab on disease activity and psychological state in patients with refractory rheumatoid arthritis
10.3760/cma.j.issn.1007-7480.2015.02.010
- VernacularTitle:托珠单抗联合治疗对难治性类风湿关节炎患者病情活动及心理状态的疗效观察
- Author:
Lefeng CHEN
;
Jianda MA
;
Xiuning WEI
;
Yingqian MO
;
Donghui ZHENG
;
Lie DAI
- Publication Type:Journal Article
- Keywords:
Arthritis,rheumatoid;
Tocilizumab;
Disease activity;
Psychological state;
Safety
- From:
Chinese Journal of Rheumatology
2015;19(2):115-118
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of tocilizumab on patients with refractory rheumatoid arthritis (RA).Methods Eighteen RA patients who were refractory to disease-modifying antirheumatic drugs (DMARDs) or tumor necrosis factor-α (TNF-α) antagonist were treated with tocilizumab were included into this study.Their clinical disease activity indices,Hospital Anxiety and Depression Scale (HADS)and safety were evaluated regularly.Statistical analysis was conducted with Mann-Whitney U test and x2 test.Results According to clinical disease activity index,44％(8/18) of patients reached treatment target 2 weeks after the first infusion of tocilizumab,and 78％ (14/18) reached treatment target after three infusions of tocilizumab.Fifty-six percent (10/18) of patients had anxiety and 22％ (4/18) had depressive symptoms at baseline.After three infusions of tocilizumab,6％(1/18) had anxiety symptoms and 11％(2/18) had depressive symptoms.The adverse effects included upper respiratory tract infection,aminotransferase elevation and neutropenia (3 patients,respectively).Conclusion Tocilizumab can rapidly and significantly improve the disease activity and psychological state with good tolerance and safety,which can be applied to Chinese refractory RA patients who failed with DMARDs or TNF-α antagonist.
